Breaking News
September 25, 2018 - Antibiotics best paediatric treatment for children’s chronic wet cough
September 25, 2018 - Looking beyond opioids: Stanford pain psychologist briefs Congress
September 25, 2018 - Organs actively fighting back against autoimmune diseases, finds study
September 25, 2018 - Lancaster professor aims to understand how genes affect smoking cessation
September 25, 2018 - Human-oriented perspective needed to better understand Parkinson’s disease
September 25, 2018 - Physical activity may have beneficial effects for people with rare Alzheimer’s disease
September 25, 2018 - FDA Updates on Valsartan Recalls
September 25, 2018 - 3-D-printed tracheal splints used in groundbreaking pediatric surgery
September 25, 2018 - Who is the designated driver, or proxy, for your health decisions?
September 25, 2018 - New chemo-optogenetic method enables multi-directional activity control of cellular processes
September 25, 2018 - Study explores link between genetic predisposition to Alzheimer’s and cardiometabolic risk factors
September 25, 2018 - NeoTract presents new clinical data from studies of UroLift System for patients with BPH
September 25, 2018 - Statins Improve Long-Term Survival After AAA Repair
September 25, 2018 - Novel brain network linked to chronic pain in Parkinson’s disease
September 25, 2018 - Researchers reassess negative pressure wound therapy as its benefit and harm remain unclear
September 25, 2018 - Older adults with ‘fall plan of care’ less likely to suffer fall-related hospitalizations
September 25, 2018 - FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
September 25, 2018 - IME Medical Electrospinning establishes state-of-the-art manufacturing lab facilities
September 25, 2018 - Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results
September 25, 2018 - How to Protect Your Eyesight
September 25, 2018 - Novel approach allows researchers to define how cells in the retina respond to diabetes
September 25, 2018 - Columbia University announces winners of 2018 Louisa Gross Horwitz Prize
September 25, 2018 - Clinical trial investigators found non-compliant with requirement to report results on EU register
September 25, 2018 - Study analyzes quality of protein supplements in function of source, treatment and storage
September 25, 2018 - FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome
September 25, 2018 - U.S. Alzheimer’s Cases to Nearly Triple by 2060
September 25, 2018 - Improving cell replacement therapy for Parkinson’s disease
September 25, 2018 - Genervon reports new findings that drug candidate GM6 attenuates Alzheimer’s disease in mice model
September 25, 2018 - FDA approves new 5 mm diameter drug-eluting stent from Cook Medical
September 25, 2018 - New $17.8 million grant ensures USC at forefront of research on tobacco-related health risks
September 25, 2018 - Researchers analyze response to combination immunotherapy for patients with rare skin cancer
September 25, 2018 - Study sheds light on how brain protein may be involved neurodevelopmental disorders
September 25, 2018 - Where to draw the line on incentives
September 25, 2018 - Solid fuel use linked with increased risk of hospitalization or death from respiratory diseases
September 25, 2018 - ‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms
September 25, 2018 - Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE
September 25, 2018 - Global leaders must make bold commitments at first-ever UN tuberculosis summit
September 25, 2018 - Brief sleep intervention works long-term to prevent child obesity
September 25, 2018 - Vaping among kids and teens a growing concern
September 25, 2018 - Public launch of products and application solutions from Porvair Laboratory Division
September 25, 2018 - Harmful H. pylori may play a role in Parkinson’s disease
September 25, 2018 - Researchers develop way to measure different types of fear of falling in patients with Parkinson’s
September 25, 2018 - Fracture causes bone density losses throughout the body
September 25, 2018 - Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder
September 25, 2018 - Hybrid theranostic complex shows high therapeutic efficacy against tumor cells
September 25, 2018 - FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 25, 2018 - Toxicological evaluation and dosimetry estimation of potential PET radiotracer
September 25, 2018 - 5 obstacles parents commonly face in child obesity treatment and how to overcome them
September 25, 2018 - Immunologist to study how Chikungunya causes devastating effects in older adults
September 25, 2018 - Rural borderland communities vulnerable to high stress impacting mental and physical health
September 25, 2018 - SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship
September 25, 2018 - Common painkiller not effective in controlling chronic pain after traumatic nerve injury
September 25, 2018 - New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer
September 25, 2018 - Environmentally-induced gene activity influences IQ test performance
September 25, 2018 - Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI
September 25, 2018 - FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
September 25, 2018 - Medical device company settles US case over false claims
September 25, 2018 - Trying to get answers: One woman’s quest for a diagnosis
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Risk of Breast Cancer’s Return Can Linger for Decades: MedlinePlus Health News

Risk of Breast Cancer’s Return Can Linger for Decades: MedlinePlus Health News

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Nov. 8, 2017 (HealthDay News) — Women treated for early stage breast cancer still face a substantial risk of recurrence up to 20 years later, a large, new study shows.

Cancer experts say the findings should help inform women’s treatment decisions.

Specifically, the researchers followed women with estrogen-receptor-positive breast cancer, which means the hormone helps fuel the cancer’s growth. Standard treatment includes hormonal therapy — with drugs that block estrogen’s effects — to help prevent a return of the cancer.

All of the women in the study, nearly 63,000, were scheduled to receive the typical five years of hormonal therapy.

Researchers found that while the women remained cancer-free for those five years, the risk for recurrence over the next 15 years was still significant.

It was greatest for women whose initial cancer had spread to multiple lymph nodes near the breast by the time it was diagnosed. Their odds of eventually having a distant recurrence — meaning the cancer spread to such tissue as the bones, liver or lungs — were as high as 41 percent.

Doctors have long known that women with estrogen-sensitive breast cancer often have recurrences many years later, said Dr. Harold Burstein, a cancer expert affiliated with the American Society of Clinical Oncology. He was not involved in the research.

“But the risks in this study are probably higher than many of us would’ve thought,” said Burstein, who’s an oncologist at the Dana-Farber Cancer Institute in Boston.

He stressed, though, that the women in the study started their treatment more than 20 years ago, and many advances have been made since.

“We’re doing a better job of treating this disease now,” Burstein said. “These numbers are probably worse than what women today would face.”

Senior researcher Dr. Daniel Hayes agreed.

“These data are scary,” said Hayes, a professor at the University of Michigan’s Comprehensive Cancer Center. “But women with ER-positive cancer are doing better now than 25 years ago.”

Still, he said, the findings give doctors and women more information for making treatment decisions.

That’s because women can opt for more than five years of hormonal therapy. Studies have shown that longer treatment further cuts the risk for recurrence.

However, that can also mean additional years of side effects — like hot flashes, sexual dysfunction and joint pain, Hayes said. If women have a clearer picture of their future odds of recurrence, he said, that could help them decide whether the treatment is worth the downsides.

For the study, Hayes’s team combined the results of 88 trials that included almost 63,000 women, all with estrogen-sensitive breast cancer. After their initial treatment with surgery, and sometimes chemotherapy, all were prescribed five years of hormonal therapy. Most received the drug tamoxifen, sometimes with newer hormonal drugs called aromatase inhibitors.

Overall, the study found, the odds of a distant recurrence varied greatly, depending on how far the original cancer had spread to nearby lymph nodes.

Women with no affected lymph nodes faced a 13 to 19 percent chance of a distant recurrence in the 15 years after their hormonal therapy ended. For those with one to three affected nodes, the odds of a distant recurrence were 20 to 26 percent. Women with four to nine nodes affected, the chances of such recurrence were 34 to 41 percent.

The findings were published Nov. 9 in the New England Journal of Medicine.

The study, Hayes said, was not designed to tell anyone what to do. “I could show these same data to two different women and get two different treatment decisions,” he said.

But, he added, “there’s no question” that women in these situations should discuss longer-term hormonal therapy with their doctor.

Dr. Neil Iyengar, who specializes in treating breast cancer at Memorial Sloan Kettering Cancer Center in New York City, described the research as “a very useful study for patients and doctors.”

Iyengar said he sees many women with earlier-stage cancers struggle with the issue of whether the side effects of hormonal therapy are worth it. The new findings, he said, might offer some women more motivation to continue — at least for the first five years, if not beyond.

But Burstein pointed out that additional hormonal therapy does not erase the possibility of a recurrence.

It won’t turn that 13 percent risk into zero risk,” he said. “But it can reduce it.”

SOURCES: Daniel Hayes, M.D., professor, breast cancer research, University of Michigan Comprehensive Cancer Center, Ann Arbor; Harold Burstein, M.D., medical oncologist, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston; Neil Iyengar, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center, New York City; Nov. 9, 2017, New England Journal of Medicine

News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.

Tagged with:

About author

Related Articles